Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARSIPPANY, N.J.--(BUSINESS WIRE)--MELINTA THERAPEUTICS ANNOUNCES STRATEGIC ACQUISITION BY CORMEDIX, UNDERSCORING ITS PORTFOLIO VALUE AND INDUSTRY LEADERSHIP.

MELINTA THERAPEUTICS ANNOUNCES STRATEGIC ACQUISITION BY CORMEDIX, UNDERSCORING ITS PORTFOLIO VALUE AND INDUSTRY LEADERSHIP

TRANSFORMATIONAL DEAL FOR CORMEDIX THAT EXPANDS AND DIVERSIFIES COMPANY'S COMMERCIAL PRODUCT PORTFOLIO, WITH SEVEN INNOVATIVE DRUG PRODUCTS AND A PIPELINE EXPANSION INDICATION WITH NEAR-TERM REVENUE GROWTH POTENTIAL TRANSACTION EXPECTED TO BE NEAR-TERM ACCRETIVE TO EPS WITH DOUBLE-DIGIT ACCRETION EXPECTED IN 2026; ANNUAL RUN-RATE SYNERGIES EXPECTED TO BE ~$35 TO $45 MILLION PRO FORMA 2025 COMBINED REVENUES ESTIMATED TO BE $305 TO $335 MILLION ADVANCES CORMEDIX'S STRATEGY TO BUILD A FORMIDABLE SPECIALTY PHARMACEUTICAL BUSINESS THROUGH A COMBINATION OF ORGANIC AND INORGANIC GROWTH DYNAMIC PLATFORM CAN BE LEVERAGED TO SUPPORT ADDITIONAL PRODUCTS AND EXPAND AS THE COMBINED COMPANY ENTERS ITS NEXT PHASE CORMEDIX TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET. BERKELEY HEIGHTS, N.J.

CORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS

 Q2 2025 NET REVENUE OF $39.7MM; NET INCOME OF $19.8MM; ADJUSTED EBITDA OF $22.4MM   COMPANY ANNOUNCES ACQUISITION OF MELINTA THERAPEUTICS   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:30 A.M. EASTERN TIME  BERKELEY HEIGHTS, N.J.

CORMEDIX INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BERKELEY HEIGHTS, N.J., JUNE 27, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 6,604,507 SHARES OF ITS COMMON STOCK. THE TOTAL GROSS PROCEEDS FROM THE OFFERING TO THE COMPANY ARE EXPECTED TO BE APPROXIMATELY $85 MILLION. IN ADDITION, CORMEDIX GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE OFFERING. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT JUNE 30, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

CORMEDIX INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BERKELEY HEIGHTS, N.J., JUNE 26, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL $85.0 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING. ALL OF THE SHARES TO BE SOLD IN THE OFFERING WILL BE OFFERED BY CORMEDIX. IN ADDITION, CORMEDIX INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING, AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BERKELEY HEIGHTS, N.J., JUNE 23, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCES AN UPDATE RELATED TO ITS LARGE DIALYSIS ORGANIZATION (LDO) CUSTOMER AND PLANNED IMPLEMENTATION IN THE SECOND HALF OF 2025.

CORMEDIX INC. ANNOUNCES CUSTOMER IMPLEMENTATION

BERKELEY HEIGHTS, N.J., MAY 30, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, WILL BE PARTICIPATING IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN NEW YORK ON JUNE 3 - 5, 2025.

CORMEDIX INC. TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE

BERKELEY HEIGHTS, N.J., MAY 15, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, WILL BE PARTICIPATING IN THE RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE, TAKING PLACE IN NEW YORK ON MAY 20-21, 2025.

CORMEDIX INC. TO PARTICIPATE IN THE RBC GLOBAL HEALTHCARE CONFERENCE

 Q1 2025 NET REVENUE OF $39.1MM; ADJUSTED EBITDA OF $23.6MM  CONFERENCE CALL SCHEDULED FOR TODAY AT 8:30 A.M. EASTERN TIME BERKELEY HEIGHTS, NJ.

CORMEDIX INC. REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BERKELEY HEIGHTS, N.J., APRIL 29, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT WILL REPORT ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, BEFORE THE MARKET OPENS ON TUESDAY, MAY 6, 2025, AND WILL HOST A CORPORATE UPDATE CONFERENCE CALL AT 8:30AM EASTERN TIME.

CorMedix Inc.

CRMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CorMedix Inc.

CRMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRMD